Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Susceptibility to infections in persons with diabetes mellitus

Amy C Weintrob, MD
Daniel J Sexton, MD
Section Editor
Peter F Weller, MD, MACP
Deputy Editor
Anna R Thorner, MD


It is widely accepted by both the medical profession and the general public that diabetics have an increased propensity to develop infections. Although several epidemiologic studies have shown that diabetics receive treatment for infections more often than non-diabetics, the magnitude of the effect of diabetes on the risk of infection remains an active research question.

Host- and organism-specific factors that may explain why people with DM are more susceptible to particular infections will be reviewed here. The clinical features, diagnosis, and treatment of specific infections that appear either to be more prevalent in diabetics or to have unique features when they occur in diabetics are discussed separately. These infections include:

Foot infections (see "Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities")

Urinary tract infections, including fungal infections (see "Emphysematous urinary tract infections")

Superficial fungal infections, such as oral candidiasis, onychomycosis, and intertrigo (see "Clinical manifestations of oropharyngeal and esophageal candidiasis" and "Onychomycosis: Epidemiology, clinical features, and diagnosis" and "Candidal intertrigo")

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Dec 05, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Mor A, Berencsi K, Nielsen JS, et al. Rates of Community-based Antibiotic Prescriptions and Hospital-treated Infections in Individuals With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study, 2004-2012. Clin Infect Dis 2016; 63:501.
  2. Bartelink ML, Hoek L, Freriks JP, Rutten GE. Infections in patients with type 2 diabetes in general practice. Diabetes Res Clin Pract 1998; 40:15.
  3. Haug JB, Harthug S, Kalager T, et al. Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome. Clin Infect Dis 1994; 19:246.
  4. Chirillo F, Bacchion F, Pedrocco A, et al. Infective endocarditis in patients with diabetes mellitus. J Heart Valve Dis 2010; 19:312.
  5. Kanafani ZA, Kourany WM, Fowler VG Jr, et al. Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. Eur J Clin Microbiol Infect Dis 2009; 28:1477.
  6. Marelli D, Laks H, Patel B, et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22:1091.
  7. Thomas MC, Mathew TH, Russ GR, et al. Early peri-operative glycaemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001; 72:1321.
  8. Marchant MH Jr, Viens NA, Cook C, et al. The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. J Bone Joint Surg Am 2009; 91:1621.
  9. Latham R, Lancaster AD, Covington JF, et al. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22:607.
  10. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999; 22:1408.
  11. Guvener M, Pasaoglu I, Demircin M, Oc M. Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. Endocr J 2002; 49:531.
  12. Estrada CA, Young JA, Nifong LW, Chitwood WR Jr. Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003; 75:1392.
  13. Ata A, Lee J, Bestle SL, et al. Postoperative hyperglycemia and surgical site infection in general surgery patients. Arch Surg 2010; 145:858.
  14. Wiseman JT, Fernandes-Taylor S, Barnes ML, et al. Predictors of surgical site infection after hospital discharge in patients undergoing major vascular surgery. J Vasc Surg 2015; 62:1023.
  15. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352.
  16. Boreland L, Scott-Hudson M, Hetherington K, et al. The effectiveness of tight glycemic control on decreasing surgical site infections and readmission rates in adult patients with diabetes undergoing cardiac surgery: A systematic review. Heart Lung 2015; 44:430.
  17. Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14:29.
  18. Llorente L, De La Fuente H, Richaud-Patin Y, et al. Innate immune response mechanisms in non-insulin dependent diabetes mellitus patients assessed by flow cytoenzymology. Immunol Lett 2000; 74:239.
  19. Hostetter MK. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 1990; 39:271.
  20. Zykova SN, Jenssen TG, Berdal M, et al. Altered cytokine and nitric oxide secretion in vitro by macrophages from diabetic type II-like db/db mice. Diabetes 2000; 49:1451.
  21. Amano H, Yamamoto H, Senba M, et al. Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in streptozotocin-induced diabetes in mice. Infect Immun 2000; 68:2925.
  22. Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001; 73:259.
  23. Al-Mashat HA, Kandru S, Liu R, et al. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes 2006; 55:487.
  24. Price CL, Hassi HO, English NR, et al. Methylglyoxal modulates immune responses: relevance to diabetes. J Cell Mol Med 2010; 14:1806.
  25. Ilyas R, Wallis R, Soilleux EJ, et al. High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology 2011; 216:126.
  26. Graham PL 3rd, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 2006; 144:318.
  27. Donders GG. Lower Genital Tract Infections in Diabetic Women. Curr Infect Dis Rep 2002; 4:536.
  28. de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002; 2:1.
  29. Ray D, Goswami R, Banerjee U, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30:312.
  30. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 2000; 33:349.
  31. Hodgson KA, Morris JL, Feterl ML, et al. Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect 2011; 13:1177.
  32. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med 2012; 367:1035.
  33. Koh GC, Weehuizen TA, Breitbach K, et al. Glyburide reduces bacterial dissemination in a mouse model of melioidosis. PLoS Negl Trop Dis 2013; 7:e2500.
  34. Koh GC, Maude RR, Schreiber MF, et al. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin Infect Dis 2011; 52:717.
  35. Ozer A, Altuntas CZ, Izgi K, et al. Advanced glycation end products facilitate bacterial adherence in urinary tract infection in diabetic mice. Pathog Dis 2015; 73.